Both of these onco-proteins are known client proteins of Hsp90, and while the levels of intracellular expression of these antigens were decreased after Hsp90 treatment, the enhanced CTL-recognition of the treated tumor cells was attributed to increased turnover of the proteins, combined with augmented peptide presentation on MHC molecules. This evidence concerns the gene HLA-C and neoplasm.